Detailed Narrative
Strong Financial Performance in 9M FY25 Driven by Premiumization
Insecticides India Limited achieved its highest-ever PAT of INR128 crores for the nine months ended December 31, 2024, representing a 36% year-on-year growth. The company's premiumization strategy has been highly successful, with premium products contributing 62% to B2C sales in 9M FY25, up from approximately 50% in previous years. The target is to further increase this contribution to 65% within the next one to two years, aiming for a minimum 20% year-on-year growth from premium products. Overall B2C volume grew 12% in 9M FY25, with premium products volume growing 19%.
Q3 FY25 Performance Amidst Lean Quarter
Despite Q3 FY25 being a lean quarter and the industry experiencing some impact, particularly on B2B sales, the company delivered strong results. Revenue from operations for Q3 FY25 stood at INR358 crores. EBITDA reached INR61 crores, a significant increase compared to INR24 crores in Q3 FY24, while PAT grew 42% year-on-year to INR17.4 crores. The EBITDA margin for the quarter was 8.6%. The company's product mix in Q3 FY25 comprised 49% insecticides, 37% herbicides, and 9% fungicides, with B2C sales accounting for 82% of total sales.
Strategic Capex and Capacity Expansion Plans
The company has significant capex plans, with approximately INR125 crores allocated over the next two years, primarily in the upcoming fiscal year. This investment will fund expansions at Sotanala (Rajasthan) for both formulation and technical manufacturing, with the formulation unit expected by mid-season and the technical unit by 2026. The Dahej plant for technical manufacturing is set to commence operations very soon in the current quarter. Additionally, land acquired through the Kaeros acquisition will be used for plant development, and a new plant for IIL Biologicals is planned at Shamli.
Kaeros Acquisition to Enhance Profitability and Market Position
The acquisition of Kaeros for INR6.3 crores (including land and business value) is a strategic move aimed at improving profitability and reducing competition. Kaeros holds import licenses for technicals, allowing the company to procure these at better prices than from competitors. Furthermore, B2B products can be transferred to Kaeros, which is expected to decrease market competition. Management anticipates Kaeros to generate over INR100 crores in net business with a double-digit margin, though detailed financial plans will be shared in future investor calls.
Focus on New Product Development and Biologicals
Insecticides India Limited launched approximately 10 new products in the current fiscal year and plans for over half a dozen more in the next fiscal. These new products, such as Shinwa, Izuki, Nissan SP, and Sofia, are performing well and are being integrated into the Focused Maharatna range. The company is also heavily investing in R&D for the biologicals segment, exploring new technologies like Nanos and Consortia to address efficacy and shelf-life challenges. A dedicated plant for IIL Biologicals is planned at Shamli to support this futuristic business.
Optimistic Industry Outlook and Working Capital Management
Management expressed an optimistic outlook for the industry, noting stability and northward movement in international raw material prices. They believe the market will readily absorb any price increases, mitigating the impact of currency depreciation. The company expects positive growth across international, B2B, and B2C businesses in Q4 FY25. Furthermore, significant improvements in working capital management were achieved, with working capital days reduced by 18 days as of December 31, 2024, and a target to further improve by 20-25 days in the next year.